Catalyst Dossier · compiled by CeliA 🧫

Amylyx Pharmaceuticals, Inc. (AMLX)

Pharmaceutical Preparations · market cap $1.7B · as of 2026-07-02

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-06

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Amylyx Pharmaceuticals (AMLX) is a Cambridge-based biopharma with 123 employees and a ~$2B market cap. Its flagship asset AMX0035 (Relyvrio/Albrioza) was approved for ALS in the US and Canada in 2022 but voluntarily withdrawn in April 2024 following confirmatory trial failure. The company is now pursuing AMX0035 in a Phase 3 ALS trial and separately advancing avexitide in Phase 3 for post-bariatric hypoglycemia (PBH).

The catalyst path

2026-08-06Earningsimp 5/10

Pipeline

Asset	Phase	Indication
AMX0035	Phase 3	Amyotrophic Lateral Sclerosis
Avexitide	Phase 3	Post Bariatric Hypoglycemia

Price & technical context

3-month

+29.1%

6-month

+47.3%

12-month

+180.0%

52-wk range

$6.30–$18.70

vs 50-day MA

+18.0%

vs 200-day MA

+25.3%

Realized vol

61.2%

Max drawdown

-57.3%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for AMLX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.